Trial efficacy data of Ryeqo in treating uterine fibroids? _ Kanghule

Author: Medicalhalo

Release time: 2025-10-19 11:44:20

Ryeqo trial for uterine fibroids

The LIBERTY randomized clinical trial showed that oral Ryeqo combination therapy (40 mg Ryeqo, 1 mg estradiol, and 0.5 mg norethindrone acetate once daily) significantly improved fibroid-related symptoms and conditions, including menorrhagia, pain, and anemia, and was well tolerated.

Two replicated, multinational, double-blind, 24-week, randomized, placebo-controlled Phase 3 studies, LIBERTY 1 and LIBERTY 2, were conducted in premenopausal women with heavy menstrual bleeding associated with uterine fibroids (≥80 mL/cycle for 2 cycles, or ≥160 mL for 1 cycle). Symptom burden and health-related quality of life were secondary endpoints and were assessed using the validated Uterine Fibroid Symptoms and Quality of Life Questionnaire, which participants completed at baseline and at weeks 12 and 24 of treatment. For this secondary analysis, the combined LIBERTY 1 and LIBERTY 2 data sets were used.

Trial results

In both trials, 509 women were randomly assigned to the combination treatment group or a placebo group. Compared with those treated with placebo, subjects who received the Ryeqo combination experienced statistically significant reductions in symptom severity (-33.5 vs -12.1; nominal P < .0001) and bleeding and pelvic discomfort subscales (-48.4 vs -17.4; nominal P < .0001) from baseline to Week 24.

Overall, the total health-related quality of life score from baseline to week 24 was significantly improved in the Ryeqo combination group compared with the placebo group (+37.6 vs +13.1; nominal P<.0001). Responder analysis showed that more women who received the Ryeqo combination reported clinically meaningful reductions in the bleeding and pelvic discomfort subscales, as well as improvements in physical and social activities, compared with women treated with placebo (nominal P < .0001).

Trial Conclusions

After 24 weeks of Ryeqo combination treatment, women with symptomatic uterine fibroids experienced significant improvements in health-related quality of life, showing improvements across all subscales, including emotional well-being, physical and social activities, and sexual function. Additionally, women reported significant reductions in overall symptom burden and distress caused by key fibroid-related symptoms.

Efficacy of Ryeqo

Ryeqo (Relugolix compound tablet) is a non-peptide small molecule gonadotropin-releasing hormone (GnRH) receptor antagonist, which is the first oral GnRH antagonist. , it can reduce the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) by binding to the GnRH receptor in the anterior pituitary gland and blocking the receptor, thereby reducing the production of estrogen and progesterone in the female ovary and alleviating the symptoms of endometriosis.

Ryeqo’s price and purchase channels

Ryeqo will be launched in the United States in May 2021. As of November 27, 2023, it has not been launched in mainland China. It is not yet available in domestic hospital pharmacies, and no relevant content has been announced.

Currently, we know from domestic professional overseas medical service organizations (such as Medical Companion Travel) that the price of a box of Ryeqo is about $14,500, but the price is not fixed due to various factors.

If you obtain it through domestic professional overseas medical service organizations (such as Medical Companion Travel), you can have the medicine mailed to your home, which is guaranteed to be genuine, affordable and cost-effective. It is recommended to consult customer service personnel for specific fees and acquisition procedures.

Menu